Galapagos NV Company Profile (NASDAQ:GLPG)

Analyst Ratings

Consensus Ratings for Galapagos NV (NASDAQ:GLPG) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: €67.00 (26.39% upside)

Analysts' Ratings History for Galapagos NV (NASDAQ:GLPG)
Show:
DateFirmActionRatingPrice TargetActions
6/17/2016Credit Suisse Group AGReiterated RatingHold$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Morgan StanleyReiterated RatingBuy$89.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/25/2016Goldman Sachs Group Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2015Bryan, Garnier & CoBoost Price TargetBuy$52.00 -> $64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015KBC SecuritiesUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2015Credit Agricole SAInitiated CoverageOutperform$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2015Nomura Holdings Inc.Initiated CoverageBuy$73.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Galapagos NV (NASDAQ:GLPG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Galapagos NV (NASDAQ:GLPG)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Galapagos NV (NASDAQ:GLPG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galapagos NV (NASDAQ:GLPG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Galapagos NV (NASDAQ:GLPG)
DateHeadline
07/21/16 07:49 AMGalapagos NV Ads (NASDAQ:GLPG) Shorts Decreased by 26.08% After Short Covering - Press Telegraph
07/20/16 05:39 PMGalapagos NV (ADR) Gap Down Today Means Higher Risks Forward - Consumer Eagle
07/20/16 07:07 AMBrokers Issue Average Price Target Of 71.75 On Galapagos NV (NASDAQ:GLPG) - Fiscal Standard
07/19/16 10:22 AMBelgium stocks higher at close of trade; BEL 20 up 0.05% - Investing.com
07/15/16 07:16 AMGalapagos NV Ads (NASDAQ:GLPG) Shorted Shares Increased By 9.22% - Consumer Eagle
07/15/16 07:16 AMGalapagos NV (NASDAQ:GLPG) Updated Price Targets - FTSE News
07/13/16 07:06 AMWere Analysts Bearish Galapagos NV (ADR) (NASDAQ:GLPG) This Week? - Press Telegraph
07/13/16 07:06 AMBroker Outlook For Galapagos NV (NASDAQ:GLPG) - Fiscal Standard
07/11/16 04:17 PMNext Weeks Broker Price Targets For Galapagos NV (NASDAQ:GLPG) - Fiscal Standard
07/07/16 07:02 AMGalapagos NV (NASDAQ:GLPG) Current Analyst Ratings - Fiscal Standard
07/05/16 04:06 PMHow Analysts Rated Galapagos NV (ADR) (NASDAQ:GLPG) Last Week? - Press Telegraph
06/23/16 07:07 AMInvitation to the Special and.
06/23/16 07:07 AMGalapagos : Invitation to EGM and nomination of Mary Kerr for Galapagos' Board of Directors
06/23/16 02:29 AMInvitation to EGM and nomination of Mary Kerr for Galapagos' Board of Directors - [at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 23 June 2016, 7.30 CET Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination ...
06/23/16 12:33 AMInvitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' Board of Directors - [GlobeNewswire] - MECHELEN, Belgium -- Galapagos NV (Euronext & NASDAQ: GLPG) has the honor to invite its Shareholders, Warrant Holders, Directors and Statutory Auditor to its Special and Extraordinary Shareholders' Meetings ...
06/20/16 01:30 PMETF’s with exposure to Galapagos NV : June 20, 2016 -
06/15/16 04:54 AMGalapagos NV :GLPG-NL: Earnings Analysis: Q1, 2016 By the Numbers : June 15, 2016 -
06/10/16 04:25 AMWhy Galapagos NV Shares Soared 30.5% in May - Motley Fool
06/09/16 03:43 PMWhy Galapagos NV Shares Soared 30.5% in May - An expansion of a program to develop drugs for cystic fibrosis led to a sharp rally in the stock.
06/09/16 04:50 AMGalapagos selected for AEX Index - GlobeNewswire (press release)
06/09/16 02:09 AMGalapagos selected for AEX Index - [at noodls] - Press release Press release 9 June 2016, 7.30 CET Mechelen, Belgium; 9 June 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) announces that Euronext has selected Galapagos NV for inclusion in the AEX®1Index ...
06/07/16 04:22 PMNew Broker Ratings For Galapagos NV (NASDAQ:GLPG) - FTSE News
06/07/16 04:22 PMNew Broker Ratings For Galapagos NV (NASDAQ:GLPG) - FTSE News
06/02/16 04:38 AMBroker Analysis: Galapagos NV (NASDAQ:GLPG) - Share Trading News - Broker Analysis: Galapagos NV (NASDAQ:GLPG)Share Trading NewsGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small ...and more »
06/01/16 03:05 PMGalapagos creates new warrant plan - [GlobeNewswire] - Mechelen, Belgium -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 865,000 warrants under new warrant plans for the benefit of employees, directors and an independent ...
05/27/16 12:12 PMGALAPAGOS : Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA) - (GlobeNewswire) - Galapagos NV (Euronext:GLPG) (NASDAQ:GLPG) reports the successful completion of the discussions with the regulatory authorities in the US and Europe and discloses the doses for the FINCH global Phase 3 program with filgotinib in RA.
05/27/16 12:12 PMGalapagos NV: FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016 - Mechelen, Belgium; 25 May 2016, 22.00 CET: Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at Digestive Disease Week (DDW [1] (#_ftn1)) 2016 in San Diego ...
05/26/16 11:19 AMGalapagos NV (GLPG) Reports Successful Completion of End-of-Phase 2 FDA , EMA Consultations in RA - StreetInsider.com - Galapagos NV (GLPG) Reports Successful Completion of End-of-Phase 2 FDA , EMA Consultations in RAStreetInsider.comGalapagos NV (NASDAQ: GLPG) reports the successful completion of the discussions with the regulatory authorities in the US and Europe and discloses the doses for the FINCH global Phase 3 program with filgotinib in RA. The FINCH program will ...and more »
05/25/16 03:16 PMFITZROY Phase 2 study with filgotinib in Crohn’s Disease presented as late breaker at DDW 2016 - [at noodls] - Press release 25 May 2016, 22.00 CET FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016 Mechelen, Belgium; 25 May 2016: Galapagos (Euronext & NASDAQ: GLPG) announces ...
05/25/16 03:04 PMFITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016 - [GlobeNewswire] - MECHELEN, Belgium -- Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at Digestive Disease Week (DDW1) ...
05/25/16 02:51 PMGalapagos' RA Drug Filgotinib to Enter Phase III in 3Q16 -
05/24/16 03:26 PMSuccessful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA) - [at noodls] - Press release Regulated information 24 May 2016, 22.00 CET FINCH Phase 3 studies to start in Q3'16 Three registration studies addressing a broad population of RA patients 100 mg and 200 mg once daily dosing ...
05/17/16 04:02 AMListing of existing shares on Euronext Brussels & Amsterdam - [at noodls] - 13c721ad-e754-4e57-85db-4b42c2f8db8b.pdf Regulated information 17 May 2016, 7.00 CET Listing of existing shares on Euronext Brussels & Amsterdam Mechelen, Belgium; 17 May 2016: Galapagos (Euronext & NASDAQ: ...
05/13/16 02:00 PMForm 6-K GALAPAGOS NV For: May 09 - Mechelen, Belgium; 9 May 2016 22.00 CET: Galapagos NV (Euronext & NASDAQ: GLPG) announces the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis (CF). Following GLPG1837, GLPG2451 is the second potentiator compound in Galapagos ...
05/13/16 12:38 PMGalapagos NV :GLPG-BE: Earnings Analysis: Q1, 2016 By the Numbers : May 13, 2016 -
05/11/16 06:42 PMETF’s with exposure to Galapagos NV : May 11, 2016 -
05/10/16 10:03 AMGalapagos NV :GLPG-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/09/16 04:08 PMGalapagos starts Phase 1 study with potentiator GLPG2451 for CF - [at noodls] - Regulated information 9 May 2016, 22.00 CET Galapagos earns $10 million milestone payment from AbbVie Mechelen, Belgium; 9 May 2016: Galapagos NV (Euronext & NASDAQ: GLPG) announces the start of a Phase ...
05/08/16 01:46 PMGalapagos NV (NASDAQ:GLPG) Broker Price Targets For The Coming Week - Share Trading News - Galapagos NV (NASDAQ:GLPG) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Galapagos NV (NASDAQ:GLPG). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
05/07/16 01:52 PMGalapagos NV (NASDAQ:GLPG) Updated Broker Price Targets - Share Trading News - Galapagos NV (NASDAQ:GLPG) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Galapagos NV (NASDAQ:GLPG). The latest reports which are currently in issue on Thursday 5th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...Galapagos NV (GLPG) Lifted to Hold at Zacks Investment ResearchWeb Breaking Newsall 2 news articles »
05/07/16 01:52 PMGalapagos NV (ADR) (NASDAQ:GLPG) Will Pocket $250M In Milestones From AbbVie Inc (NYSE:ABBV) - Market Exclusive - Market ExclusiveGalapagos NV (ADR) (NASDAQ:GLPG) Will Pocket $250M In Milestones From AbbVie Inc (NYSE:ABBV)Market ExclusiveThe cystic fibrosis deal between AbbVie Inc (NYSE:ABBV) and Galapagos NV (ADR) (NASDAQ:GLPG) that was struck back in 2013 seems is coming to its conclusion and the Belgian biotech will now pocket $250 million (€218 million). The amount is more ...Recently Changed Price Targets On Galapagos NV (NASDAQ:GLPG)Risers & FallersGalapagos NV Ads (NASDAQ:GLPG) Sellers Covered 10.59% of Their ShortsB.O.D.Y Confidentialall 4 news articles »
05/01/16 02:02 PMGalapagos NV Ads (NASDAQ:GLPG) Short Interest Decreased By 10.59% - B.O.D.Y Confidential - Galapagos NV Ads (NASDAQ:GLPG) Short Interest Decreased By 10.59%B.O.D.Y ConfidentialThe stock of Galapagos NV Ads (NASDAQ:GLPG) registered a decrease of 10.59% in short interest. GLPG's total short interest was 471,100 shares in May as published by FINRA. Its down 10.59% from 526,900 shares, reported previously. With 57,100 shares ...
04/29/16 10:16 AMGilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales -
04/29/16 02:11 AMGalapagos and AbbVie expand their cystic fibrosis collaboration - [at noodls] - Draft webcast 2015-04-20 Darwin 2 W12_draft for notice SENT.pptm Regulated information 29 April 2016, 7.00 CET Strong commitment from Galapagos and AbbVie to accelerate development of a triple combination ...
04/28/16 03:59 PMGalapagos kick-starts 2016 with Q1 cash position of €988 M - [at noodls] - Regulated information 28 April 2016, 22.00 CET First quarter financial results: Group revenues €14.8 M Group net profit €35.9 M ... This is an abstract of the original noodl. To continue reading this document, ...
04/28/16 01:58 PMBroker Roundup For Galapagos NV (NASDAQ:GLPG) - Share Trading News - Broker Roundup For Galapagos NV (NASDAQ:GLPG)Share Trading News06/08/2015 – Morgan Stanley began new coverage on Galapagos NV giving the company a “overweight” rating. They now have a USD 73 price target on the stock. The share price of Galapagos NV (NASDAQ:GLPG) was down -0.31% during the last trading ...
04/24/16 01:35 PMNext Weeks Broker Price Targets For Galapagos NV (NASDAQ:GLPG) - Share Trading News - Next Weeks Broker Price Targets For Galapagos NV (NASDAQ:GLPG)Share Trading NewsGalapagos NV has a 50 day moving average of 43.37 and a 200 day moving average of 48.37. The stock's market capitalization is 1.78B, it has a 52-week low of 37.03 and a 52-week high of 65.70. The share price of the company (NASDAQ:GLPG) was up ...
04/23/16 02:02 PMGalapagos NV (NASDAQ:GLPG) Updated Broker Ratings - Risers & Fallers - Galapagos NV (NASDAQ:GLPG) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Galapagos NV (NASDAQ:GLPG). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...
04/23/16 02:02 PMGalapagos NV (GLPG) Reports 20-Week Results from FITZROY Study - StreetInsider.com - Galapagos NV (GLPG) Reports 20-Week Results from FITZROY StudyStreetInsider.comGalapagos NV (Euronext & NASDAQ: GLPG) reported 20-week results from its FITZROY study with the investigational, selective JAK1 inhibitor filgotinib in Crohn's disease. 174 patients with moderately to severely active Crohn's disease were enrolled in ...and more »
04/22/16 02:20 AMGalapagos reports additional data with filgotinib from the Phase 2 FITZROY study - [at noodls] - Press release Regulated information 21 April 2016, 22.00 CET Filgotinib: an investigational JAK-inhibitor shows efficacy in Crohn's disease Clinical responses continued from week 10 to week 20 Safety profile ...

Social

About Galapagos NV

Galapagos NV logoGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLPG
  • CUSIP:
Key Metrics:
  • Previous Close: $53.01
  • 50 Day Moving Average: $54.25
  • 200 Day Moving Average: $48.91
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $2.43B
  • Beta: 2.14
  • Current Year EPS Consensus Estimate: $-1.47 EPS
  • Next Year EPS Consensus Estimate: $-2.57 EPS
Additional Links:
Galapagos NV (NASDAQ:GLPG) Chart for Monday, July, 25, 2016